Clinical Trial Update: A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study assessing safety and effectiveness of ustekinumab for moderate to severe plaque-type psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Stelara (ustekinumab)

Snippet

Sponsor: Centocor Research & Development, Inc. | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2012-08-24